Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Retained Earnings (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Retained Earnings data on record, last reported at -$1.5 billion in Q4 2025.

  • For Q4 2025, Retained Earnings changed N/A year-over-year to -$1.5 billion; the TTM value through Dec 2025 reached -$1.5 billion, changed N/A, while the annual FY2025 figure was -$1.5 billion, N/A changed from the prior year.
  • Retained Earnings reached -$1.5 billion in Q4 2025 per RCUS's latest filing, down from -$1.4 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$2000.0 in Q1 2021 and bottomed at -$1.5 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$472.7 million, with a median of -$8.5 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.0% in 2021, then crashed 232900.0% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$1.0 million in 2021, then crashed by 54100.0% to -$542.0 million in 2022, then crashed by 56.64% to -$849.0 million in 2023, then decreased by 22.26% to -$1.0 billion in 2024, then tumbled by 43.06% to -$1.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.5 billion in Q4 2025, -$1.4 billion in Q3 2025, and -$1.2 billion in Q2 2025.